Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts, Till 2035
The cell therapy manufacturing market is valued at USD 4.90 billion in 2024 growing at a CAGR of 9.90% during the forecast period 2024-2035.
Currently, over 300 cell therapies are in various stages of clinical development, with more than 1,930 clinical studies initiated since 2019 focusing on these candidates. Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta® achieved sales exceeding USD 1.5 billion, while Tecartus® generated sales of USD 370 million in 2023.
Given the substantial evidence supporting the clinical benefits and therapeutic potential of cell therapies, stakeholders are now concentrating on optimizing the manufacturing processes for these therapies. In recent years, numerous advanced automation technologies and platforms have been developed, demonstrating the potential to significantly lower manufacturing costs, thus making these products more affordable. One notable innovation, GMP-In-A Box, offers several advantages, including increased throughput, reduced idle time between batch runs, and decreased manual labor. However, the overall automation process faces challenges due to the complex steps involved in cell therapy manufacturing. Additionally, the lack of specialized infrastructure and trained personnel in this field poses significant obstacles to the growth of this segment.
Key Market Segments
Type of Cell Therapy
- T Cell Therapies
- NK Cell Therapies
- Dendritic Cell Therapies
- Stem Cell Therapies
- Autologous
- Allogeneic
- Unspecified
- Clinical
- Commercial
- In-house Manufacturing
- Contract Manufacturing Organization
- North America
- Europe
- Asia-Pacific
- Rest of the World
- A general introduction to cell therapies, along with information on the key challenges and factors influencing the cell therapy manufacturing market. It provides details on the automation tools and technologies being utilized for improving manufacturing processes and the future prospects in this domain.
- An overview of the current market landscape with respect to the industry players engaged in the manufacturing of cell-based therapies. It features information on their company size, year of establishment, location of headquarters, location of manufacturing facilities, type of manufacturer (in-house manufacturers and contract manufacturing organizations), type of cell manufactured (immune cells, stem cells and others), source of cells (autologous and allogeneic), scale of operation (preclinical, clinical and commercial) and additional services offered (research and development, cell culture development, cell banking, documentation, testing, packaging, supply chain management and regulatory support).
- An overview of the current cell therapy manufacturing market landscape with respect to the non-industry players engaged in the manufacturing of cell-based therapies. It features information on their year of establishment, location of headquarters, location of manufacturing facilities, type of manufacturer (in-house manufacturers and contract manufacturing organizations), type of cell manufactured (immune cells, stem cells and others), source of cells (autologous and allogeneic), scale of operation (preclinical, clinical and commercial) and additional services offered (research and development, cell culture development, cell banking, documentation, testing, packaging, supply chain management and regulatory support).
- A discussion on cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
- An overview of the several roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing process.
- An elaborate discussion on the role of technology automation in cell therapy manufacturing in order to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their cell therapy production process.
- Elaborate profiles of industry players involved in cell therapy manufacturing. Each profile features a brief overview of the company, along with details related to its service portfolio, its manufacturing capabilities and facilities, recent developments and an informed future outlook.
- Elaborate profiles of non-industry players involved in cell therapy manufacturing, featuring an overview of the organization, along with details related to their service portfolio and manufacturing facilities.
- A discussion on non-profit organizations in cell therapy manufacturing, featuring a list of organizations that are actively involved in the development and production of cell-based therapies, across different geographical locations, along with information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.
- An analysis of completed, ongoing and planned clinical trial, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, study design, most active players (in terms of number of clinical trials conducted) and geographical distribution of trials.
- A detailed analysis of the recent partnerships and collaborations inked by players focused on the manufacturing of cell-based therapies, since 2016, based on several relevant parameters, such as the year of partnership, type of partnership, type of cells manufactured, scale of operation, most active players (in terms of number of partnerships) and geographical distribution.
- An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2017-2024, based on several relevant parameters, such as year of expansion, type of expansion, type of cell manufactured, scale of operation, location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
- An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
- An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry and non-industry stakeholders in the public domain, highlighting the distribution of the available capacity (in terms of cleanroom area and number of cleanrooms) on the basis of scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
- Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions.
- A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
- A qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
- A detailed total cost of ownership analysis based on company size, for cell therapy manufacturing organizations, over a period of 20 years.
- A detailed cell therapy manufacturing market forecast analysis in order to estimate the existing market size and future opportunity over the next decade. Based on multiple parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such therapies, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long-term, for the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
- Detailed projections of the current and future cell therapy manufacturing market across different types of cell therapy, such as T cell therapies, NK cell therapies, dendritic cell therapies, and stem cell therapies.
- Detailed projections of the current and future cell therapy manufacturing industry across different sources of cell, such as autologous, allogeneic and unspecified.
- Detailed projections of the current and future cell therapy manufacturing market across different scales of operation, such as clinical and commercial.
- Detailed projections of the current and future cell therapy manufacturing revenue across different types of manufacturers, such as in-house manufacturers and contract manufacturing organizations.
- Detailed projections of the current and future cell therapy manufacturing market across various geographies, such as North America, Europe, Asia Pacific, and Rest of the World.
- A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
- Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.
- The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
- Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
- The report provides stakeholders with a pulse on the Cell Therapy Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.
- AGC Biologics
- BioNTech Innovative Manufacturing Services
- Cell and Gene Therapy Catapult
- Cell Therapies
- Center for Cell and Gene Therapy, Baylor College of Medicine
- Centre for Cell Manufacturing Ireland, National University of Ireland
- Charles River Laboratories
- Clinical Cell and Vaccine Production Facility, University of Pennsylvania
- FUJIFILM Cellular Dynamics
- Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
- KBI Biopharma
- Laboratory for Cell and Gene Medicine, Stanford University
- Lonza
- MEDINET
- Minaris Regenerative Medicine
- Molecular and Cellular Therapeutics, University of Minnesota
- Newcastle Cellular Therapies Facility, Newcastle University
- Nikon CeLL Innovation
- Rayne Cell Therapy Suite, King’s College London
- RoslinCT
- Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
- Sydney Cell and Gene Therapy
- Thermo Fisher Scientific
- WuXi AppTec
- 1. Preface
- 1.1. Introduction
- 1.2. Market Share Insights
- 1.3. Key Market Insights
- 1.4. Report Coverage
- 1.5. Key Questions Answered
- 1.6. Chapter Outlines
- 2. Research Methodology
- 2.1. Chapter Overview
- 2.2. Research Assumptions
- 2.3. Project Methodology
- 2.4. Forecast Methodology
- 2.5. Robust Quality Control
- 2.6. Key Market Segmentations
- 2.7. Key Considerations
- 2.7.1. Demographics
- 2.7.2. Economic Factors
- 2.7.3. Government Regulations
- 2.7.4. Supply Chain
- 2.7.5. Covid Impact / Related Factors
- 2.7.6. Market Access
- 2.7.7. Healthcare Policies
- 2.7.8. Industry Consolidation
- 3. Economic And Other Project Specific Considerations
- 3.1. Chapter Overview
- 3.2. Market Dynamics
- 3.2.1. Time Period
- 3.2.1.1. Historical Trends
- 3.2.1.2. Current And Forecasted Estimates
- 3.2.2. Currency Coverage
- 3.2.2.1. Overview Of Major Currencies Affecting The Market
- 3.2.2.2. Impact Of Currency Fluctuations On The Industry
- 3.2.3. Foreign Exchange Impact
- 3.2.3.1. Evaluation Of Foreign Exchange Rates And Their Impact On Market
- 3.2.3.2. Strategies For Mitigating Foreign Exchange Risk
- 3.2.4. Recession
- 3.2.4.1. Historical Trends Analysis Of Past Recessions And Lessons Learnt
- 3.2.4.2. Assessment Of Current Economic Conditions And Potential Impact On The Market
- 3.2.5. Inflation
- 3.2.5.1. Measurement And Analysis Of Inflationary Pressures In The Economy
- 3.2.5.2. Potential Impact Of Inflation On The Market Evolution
- 4. Executive Summary
- 5. Introduction
- 5.1. Chapter Overview
- 5.2. Introduction To Cell-based Therapies
- 5.2.1. Comparison Of Cell-based Therapies And Other Biotechnological Products
- 5.2.2. Classification Of Advanced Therapy Medicinal Products (Atmps)
- 5.2.3. Current Market Landscape Of Atmps
- 5.3. Overview Of Cell Therapy Manufacturing
- 5.4. Cell Therapy Manufacturing Models
- 5.4.1. Centralized Manufacturing
- 5.4.2. Decentralized Manufacturing
- 5.5. Scalability Of Cell Therapy Manufacturing Processes
- 5.5.1. Scale-up
- 5.5.2. Scale-out
- 5.6. Types Of Cell Therapy Manufacturers
- 5.7. Key Challenges For Manufacturing Cell Therapies
- 5.8. Key Factors Influencing Cell Therapy Manufacturing
- 5.8.1. Characterization
- 5.8.2. Cost Of Goods
- 5.9. Automation Of Cell Therapy Manufacturing Processes
- 5.10. Cell Therapy Manufacturing Supply Chain
- 5.11. Future Perspectives
- 6. Cell Therapy Manufacturers (Industry Players): Market Landscape
- 6.1. Chapter Overview
- 6.2. Industry Players: Overall Market Landscape
- 6.2.1. Analysis By Year Of Establishment
- 6.2.2. Analysis By Company Size
- 6.2.3. Analysis By Location Of Headquarters
- 6.2.4. Analysis By Company Size And Location Of Headquarters
- 6.2.5. Analysis By Location Of Manufacturing Facility
- 6.2.6. Analysis By Type Of Manufacturer
- 6.2.7. Analysis By Location Of Headquarters And Type Of Manufacturer
- 6.2.8. Analysis By Type Of Cell Manufactured
- 6.2.9. Analysis By Location Of Headquarters And Type Of Cell Manufactured
- 6.2.10. Analysis By Source Of Cells
- 6.2.11. Analysis By Type Of Cell Manufactured And Source Of Cells
- 6.2.12. Analysis By Scale Of Operation
- 6.2.13. Analysis By Additional Services Offered
- 6.2.14. Analysis By Company Size And Additional Services Offered
- 7. Cell Therapy Manufacturers (Non-industry Players): Market Landscape
- 7.1. Chapter Overview
- 7.2. Non-industry Players: Overall Market Landscape
- 7.2.1. Analysis By Year Of Establishment
- 7.2.2. Analysis By Location Of Headquarters
- 7.2.3. Analysis By Location Of Manufacturing Facility
- 7.2.4. Analysis By Type Of Manufacturer
- 7.2.5. Analysis By Location Of Headquarters And Type Of Manufacturer
- 7.2.6. Analysis By Type Of Cell Manufactured
- 7.2.7. Analysis By Location Of Headquarters And Type Of Cell Manufactured
- 7.2.8. Analysis By Source Of Cells
- 7.2.9. Analysis By Type Of Cell Manufactured And Source Of Cells
- 7.2.10. Analysis By Scale Of Operation
- 7.2.11. Analysis By Additional Services Offered
- 8. Regulatory Landscape
- 8.1. Chapter Overview
- 8.2. Current Scenario
- 8.2.1. Regulatory Guidelines In North America
- 8.2.2. Regulatory Guidelines In Europe
- 8.2.3. Regulatory Guidelines In Asia Pacific
- 8.2.3.1. Regulatory Guidelines In Japan
- 8.2.3.2. Regulatory Guidelines In China
- 8.2.4. Conditional Approvals
- 8.3. Regulatory Authorities For Cell Therapy Manufacturing
- 8.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
- 8.4. Summary Of Guidelines For Early-stage Manufacturing Of Cell Therapies
- 8.5. Existing Challenges To Early-stage Manufacturing Of Cell Therapies
- 8.6. Variability In Regulatory Guidelines Across Different Geographies
- 9. Roadmaps For Overcoming Challenges
- 9.1. Chapter Overview
- 9.2. Roadmap For The Us
- 9.2.1. Cell Processing
- 9.2.2. Cell Preservation, Distribution And Handling
- 9.2.3. Process Automation And Data Analytics
- 9.2.4. Process Monitoring And Quality Control
- 9.2.5. Standardization And Regulatory Support
- 9.2.6. Workforce Development
- 9.2.7. Supply Chain And Logistics
- 9.3. Roadmaps For Other Geographies
- 9.3.1. Europe
- 9.3.2. Asia Pacific
- 10. Automation Technologies For Cell Therapy Manufacturing
- 10.1. Chapter Overview
- 10.2. Automation Of Cell Therapy Manufacturing Processes
- 10.2.1. Closed Systems
- 10.2.2. Single-use Systems
- 10.2.3. Modular Systems
- 10.3. Growth Drivers And Roadblocks
- 10.4. Case Studies
- 10.4.1. Roadmap To Develop An Automated Cell Manufacturing / Processing Device
- 10.4.2. Automating The Cell Therapy Manufacturing Process
- 10.5. Gmp-in-a-box
- 10.6. List Of Automated And Closed Cell Therapy Processing Systems
- 10.7. Comparative Analysis Of Manual And Automated Processes
- 11. Company Profiles: Industry Players
- 11.1. Chapter Overview
- 11.2. Service Providers In North America
- 11.2.1. Agc Biologics
- 11.2.1.1. Company Overview
- 11.2.1.2. Financial Information
- 11.2.1.3. Service Portfolio
- 11.2.1.4. Manufacturing Facilities And Capabilities
- 11.2.1.5. Recent Developments And Future Outlook
- 11.2.2. Charles River Laboratories
- 11.2.2.1. Company Overview
- 11.2.2.2. Financial Information
- 11.2.2.3. Service Portfolio
- 11.2.2.4. Manufacturing Facilities And Capabilities
- 11.2.2.5. Recent Developments And Future Outlook
- 11.2.3. Fujifilm Cellular Dynamics
- 11.2.3.1. Company Overview
- 11.2.3.2. Service Portfolio
- 11.2.3.3. Manufacturing Facilities And Capabilities
- 11.2.3.4. Recent Developments And Future Outlook
- 11.2.4. Kbi Biopharma
- 11.2.4.1. Company Overview
- 11.2.4.2. Financial Information
- 11.2.4.3. Service Portfolio
- 11.2.4.4. Manufacturing Facilities And Capabilities
- 11.2.4.5. Recent Developments And Future Outlook
- 11.2.5. Thermo Fisher Scientific
- 11.2.5.1. Company Overview
- 11.2.5.2. Financial Information
- 11.2.5.3. Service Portfolio
- 11.2.5.4. Manufacturing Facilities And Capabilities
- 11.2.5.5. Recent Developments And Future Outlook
- 11.2.6. Wuxi Advanced Therapies
- 11.2.6.1. Company Overview
- 11.2.6.2. Service Portfolio
- 11.2.6.3. Manufacturing Facilities And Capabilities
- 11.2.6.4. Recent Developments And Future Outlook
- 11.3. Service Providers In Europe
- 11.3.1. Biontech Innovative Manufacturing Services
- 11.3.1.1. Company Overview
- 11.3.1.2. Service Portfolio
- 11.3.1.3. Manufacturing Facilities And Capabilities
- 11.3.1.4. Recent Developments And Future Outlook
- 11.3.2. Cell And Gene Therapy Catapult
- 11.3.2.1. Company Overview
- 11.3.2.2. Service Portfolio
- 11.3.2.3. Manufacturing Facilities And Capabilities
- 11.3.2.4. Recent Developments And Future Outlook
- 11.3.3. Lonza
- 11.3.3.1. Company Overview
- 11.3.3.2. Financial Information
- 11.3.3.3. Service Portfolio
- 11.3.3.4. Manufacturing Facilities And Capabilities
- 11.3.3.5. Recent Developments And Future Outlook
- 11.3.4. Roslinct
- 11.3.4.1. Company Overview
- 11.3.4.2. Service Portfolio
- 11.3.4.3. Manufacturing Facilities And Capabilities
- 11.3.4.4. Recent Developments And Future Outlook
- 11.4. Service Providers In Asia Pacific
- 11.4.1. Cell Therapies
- 11.4.1.1. Company Overview
- 11.4.1.2. Service Portfolio
- 11.4.1.3. Manufacturing Facilities And Capabilities
- 11.4.1.4. Recent Developments And Future Outlook
- 11.4.2. Minaris Regenerative Medicine
- 11.4.2.1. Company Overview
- 11.4.2.2. Service Portfolio
- 11.4.2.3. Manufacturing Facilities And Capabilities
- 11.4.2.4. Recent Developments And Future Outlook
- 11.4.3. Medinet
- 11.4.3.1. Company Overview
- 11.4.3.2. Service Portfolio
- 11.4.3.3. Manufacturing Facilities And Capabilities
- 11.4.3.4. Recent Developments And Future Outlook
- 11.4.4. Nikon Cell Innovation
- 11.4.4.1. Company Overview
- 11.4.4.2. Service Portfolio
- 11.4.4.3. Manufacturing Facilities And Capabilities
- 11.4.4.4. Recent Developments And Future Outlook
- 12. Company Profiles: Non-industry Players
- 12.1. Chapter Overview
- 12.2. Center For Cell And Gene Therapy, Baylor College Of Medicine
- 12.2.1. Overview
- 12.2.2. Service Portfolio
- 12.2.3. Manufacturing Facilities And Capabilities
- 12.3. Centre For Cell Manufacturing Ireland, National University Of Ireland
- 12.3.1. Overview
- 12.3.2. Service Portfolio
- 12.3.3. Manufacturing Facilities And Capabilities
- 12.4. Clinical Cell And Vaccine Production Facility, University Of Pennsylvania
- 12.4.1. Overview
- 12.4.2. Service Portfolio
- 12.4.3. Manufacturing Facilities And Capabilities
- 12.5. Guy’s And St. Thomas’ Gmp Facility, Guy’s Hospital
- 12.5.1. Overview
- 12.5.2. Service Portfolio
- 12.5.3. Manufacturing Facilities And Capabilities
- 12.6. Laboratory For Cell And Gene Medicine, Stanford University
- 12.6.1. Overview
- 12.6.2. Service Portfolio
- 12.6.3. Manufacturing Facilities And Capabilities
- 12.7. Molecular And Cellular Therapeutics, University Of Minnesota
- 12.7.1. Overview
- 12.7.2. Service Portfolio
- 12.7.3. Manufacturing Facilities And Capabilities
- 12.8. Newcastle Cellular Therapies Facility, Newcastle University
- 12.8.1. Overview
- 12.8.2. Service Portfolio
- 12.8.3. Manufacturing Facilities And Capabilities
- 12.9. Rayne Cell Therapy Suite, King’s College London
- 12.9.1. Overview
- 12.9.2. Service Portfolio
- 12.9.3. Manufacturing Facilities And Capabilities
- 12.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre For Regenerative Medicine
- 12.10.1. Overview
- 12.10.2. Service Portfolio
- 12.10.3. Manufacturing Facilities And Capabilities
- 12.11. Sydney Cell And Gene Therapy
- 12.11.1. Overview
- 12.11.2. Service Portfolio
- 12.11.3. Manufacturing Facilities And Capabilities
- 13. Non-profit Organizations In Cell Therapy Manufacturing
- 13.1. Chapter Overview
- 13.2. Cell Therapy Manufacturing: Non-profit Organizations
- 13.2.1. Cellcan
- 13.2.2. Cell Therapy Manufacturing Cooperative Research Center
- 13.2.3. National Cell Manufacturing Consortium (Ncmc)
- 13.2.4. California Institute Of Regenerative Medicine (Cirm)
- 13.3. Cell Therapy Manufacturing: International Societies
- 14. Clinical Trial Analysis
- 14.1. Chapter Overview
- 14.2. Scope And Methodology
- 14.3. Cell Therapies: Clinical Trial Analysis
- 14.3.1. Analysis By Trial Registration Year
- 14.3.2. Analysis By Tria Registration Year And Enrolled Patient Population
- 14.3.3. Analysis By Trial Status
- 14.3.4. Analysis By Trial Registration Year And Trial Status
- 14.3.5. Analysis By Trial Phase
- 14.3.6. Analysis Of Number Of Clinical Trials And Enrolled Patient Population By Trial Phase
- 14.3.7. Analysis By Type Of Sponsor / Collaborator
- 14.3.8. Analysis By Patient Segment
- 14.3.9. Analysis By Study Design
- 14.3.10. Most Active Players: Analysis By Number Of Registered Trials
- 14.3.11. Analysis By Number Of Trials And Geography
- 14.3.12. Analysis By Number Of Trials, Trial Status And Geography
- 14.3.13. Analysis By Enrolled Patient Population, Trial Status And Geography
- 15. Partnerships And Collaborations
- 15.1. Chapter Overview
- 15.2. Partnership Models
- 15.3. Cell Therapy Manufacturing: List Of Partnerships
- 15.3.1. Analysis By Year Of Partnership
- 15.3.2. Analysis By Type Of Partnership
- 15.3.3. Analysis By Year And Type Of Partnership
- 15.4. Analysis By Type Of Cells
- 15.5. Analysis By Scale Of Operation
- 15.6. Analysis By Region
- 15.6.1. Country-wise Distribution
- 15.6.2. Continent-wise Distribution
- 15.7. Most Active Players: Analysis By Number Of Partnerships
- 15.8. Cell Therapy Manufacturing: List Of Mergers And Acquisitions
- 15.8.1. Analysis By Year Of Agreement
- 15.8.2. Analysis By Type Of Agreement
- 15.8.3. Analysis By Year Of Acquisition And Type Of Cells
- 15.8.4. Analysis By Region
- 15.8.4.1. Country-wise Distribution
- 15.8.4.2. Continent-wise Distribution
- 15.8.4.3. Intercontinental And Intracontinental Deals
- 15.8.5. Ownership Change Matrix
- 16. Recent Expansions
- 16.1. Chapter Overview
- 16.2. Cell Therapy Manufacturing: List Of Expansions
- 16.2.1. Analysis By Year Of Expansion
- 16.2.2. Analysis By Type Of Expansion
- 16.2.3. Analysis By Type Of Cell Manufactured
- 16.2.4. Analysis By Scale Of Operation
- 16.2.5. Analysis By Location Of Manufacturing Facility
- 16.2.6. Analysis By Type Of Expansion And Location Of Manufacturing Facility
- 16.2.7. Most Active Players: Analysis By Number Of Expansions
- 16.2.8. Most Active Players: Analysis By Area Of Expansion
- 16.2.9. Analysis By Year And Location Of Manufacturing Facility
- 17. Big Pharma Initiatives
- 17.1. Chapter Overview
- 17.2. List Of Cell Therapy Manufacturing Focused Initiatives Of Big Pharma Players
- 17.2.1. Analysis By Number Of Initiatives
- 17.2.2. Analysis By Year Of Initiative
- 17.2.3. Analysis By Type Of Initiative
- 17.2.3.1. Analysis By Type Of Partnership
- 17.2.3.2. Analysis By Type Of Expansion
- 17.2.4. Analysis By Types Of Cells Manufactured
- 17.2.5. Analysis By Scale Of Operation
- 17.2.6. Analysis Of Big Pharma Players By Year Of Initiative
- 17.2.7. Analysis By Year And Type Of Initiative
- 17.2.8. Analysis Of Big Pharma Players By Types Of Cells Manufactured
- 17.2.9. Analysis Of Big Pharma Players By Scale Of Operation
- 17.3. Competitive Benchmarking Of Big Pharmaceutical Players
- 17.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
- 17.3.2. Spider Web Analysis: Big Pharmaceutical Players
- 18. Capacity Analysis
- 18.1. Chapter Overview
- 18.2. Industry Players: Key Assumptions And Methodology
- 18.2.1. Cell Therapy Manufacturing: Installed Global Capacity (Number Of Cleanrooms)
- 18.2.1.1. Analysis By Company Size
- 18.2.1.2. Analysis By Scale Of Operation
- 18.2.1.3. Analysis By Location Of Manufacturing Facility
- 18.2.1.4. Analysis By Company Size And Location Of Manufacturing Facility
- 18.2.1.5. Analysis By Scale Of Operation And Location Of Manufacturing Facility
- 18.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
- 18.2.2.1. Analysis By Company Size
- 18.2.2.2. Analysis By Scale Of Operation
- 18.2.2.3. Analysis By Location Of Manufacturing Facility
- 18.2.2.4. Analysis By Company Size And Location Of Manufacturing Facility
- 18.2.2.5. Analysis By Scale Of Operation And Location Of Manufacturing Facility
- 18.3. Non- Industry Players: Key Assumptions And Methodology
- 18.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number Of Cleanrooms)
- 18.3.1.1. Analysis By Scale Of Operation
- 18.3.1.2. Analysis By Location Of Manufacturing Facility
- 18.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
- 18.3.2.1. Analysis By Scale Of Operation
- 18.3.2.2. Analysis By Location Of Manufacturing Facility
- 18.4. Concluding Remarks
- 19. Demand Analysis
- 19.1. Chapter Overview
- 19.2. Scope And Methodology
- 19.3 Global Demand For Cell Therapy Manufacturing
- 19.4. Global Clinical Demand For Cell Therapy Manufacturing
- 19.4.1. Analysis By Type Of Cell Therapy
- 19.4.2. Analysis By Geography
- 19.5. Global Commercial Demand For Cell Therapy Manufacturing
- 19.5.1. Commercial Demand: Analysis By Type Of Cell Therapy
- 19.5.2. Commercial Demand: Analysis By Geography
- 20. Cost Price Analysis
- 20.1. Chapter Overview
- 20.2. Factors Contributing To The High Price Of Cell Therapies
- 20.3. Pricing Models For Cell Therapies
- 20.3.1. Based On Associated Costs For T-cell Therapies
- 20.3.2. Based On Associated Costs For Stem Cell Therapies
- 20.3.3. Based On Availability Of Competing Products
- 20.3.4. Based On Target Patient Segment
- 20.3.5. Based On The Opinions Of Industry Experts
- 20.4. Cell Therapy Cost Optimization
- 20.4.1. Role Of Cost Of Goods Sold
- 20.4.2. Role Of Automation
- 20.5. Role Of Cell Therapy Contract Manufacturing Organizations
- 20.6. Reimbursement-related Considerations For Cell Therapies
- 20.6.1. Case Study: The National Institute For Health And Care Excellence’s (Nice) Appraisal Of Car-t Therapies
- 21. Make Versus Buy Decision Making Framework
- 21.1. Chapter Overview
- 21.2. Assumptions And Key Parameters
- 21.3. Cell Therapy Manufacturing: Make Versus Buy Decision Making
- 21.3.1. Scenario 1
- 21.3.2. Scenario 2
- 21.3.3. Scenario 3
- 21.3.4. Scenario 4
- 21.4. Concluding Remarks
- 22. Total Cost Of Ownership For Cell Therapy Manufacturing Organizations
- 22.1. Chapter Overview
- 22.2. Key Parameters
- 22.3. Assumptions And Methodology
- 22.4. Sample Dataset For The Estimation Of Total Cost Of Ownership
- 22.5. Total Cost Of Ownership For Mid-sized Cell Therapy Manufacturing Organizations, Y0-y20
- 22.6. Total Cost Of Ownership For Mid-sized Cell Therapy Manufacturing Organizations: Analysis By Capex And Opex, Y0 And Y20
- 22.6.1. Total Cost Of Ownership For Mid-sized Cell Therapy Manufacturing Organizations: Analysis By Capex, Y0
- 22.6.2. Total Cost Of Ownership For Mid-sized Cell Therapy Manufacturing Organizations: Analysis By Opex, Y1-y20
- 23. Global Cell Therapy Manufacturing Market
- 23.1. Chapter Overview
- 23.2. Scope Of The Forecast
- 23.3. Input Data And Key Assumptions
- 23.4. Forecast Methodology
- 23.5. Global Cell Therapy Manufacturing Market, Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 23.5.1. Scenario Analysis
- 23.5.1.1. Conservative Scenario
- 23.5.1.2. Optimistic Scenario
- 23.6. Key Market Segmentations
- 24. Cell Therapy Manufacturing Market, By Type Of Cell Therapy
- 24.1. Chapter Overview
- 24.2. Key Assumptions And Methodology
- 24.3. Cell Therapy Manufacturing Market: Distribution By Type Of Cell Therapy, 2022, 2024 And 2035
- 24.3.1. T Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.1.1. Car-t Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.1.2. Tcr Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.1.3. Til Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.2. Stem Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.3. Dendritic Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.3.4. Nk Cell Therapies: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 24.4. Data Triangulation And Validation
- 25. Cell Therapy Manufacturing Market, By Source Of Cells
- 25.1. Chapter Overview
- 25.2. Key Assumptions And Methodology
- 25.3. Cell Therapy Manufacturing Market: Distribution By Source Of Cells, 2022, 2024 And 2035
- 25.3.1. Autologous Source Of Cells: Historical Trends (2022-2035) And Forecasted Estimates (2024-2035)
- 25.3.2. Allogeneic Source Of Cells: Historical Trends (2022-2035) And Forecasted Estimates (2024-2035)
- 25.3.3. Unspecified Source Of Cells: Historical Trends (2022-2035) And Forecasted Estimates (2024-2035)
- 25.4. Data Triangulation And Validation
- 26. Cell Therapy Manufacturing Market, By Scale Of Operation
- 26.1. Chapter Overview
- 26.2. Key Assumptions And Methodology
- 26.3. Cell Therapy Manufacturing Market: Distribution By Scale Of Operation, 2022, 2024 And 2035
- 26.3.1. Clinical Scale: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035
- 26.4. Clinical Cell Therapy Manufacturing Market, By Type Of Therapy
- 26.4.1. Clinical Scale Manufacturing Market For T Cell Therapies, 2022-2035
- 26.4.1.1. Clinical Scale Manufacturing Market For T Cell Therapies: Distribution By Type Of Therapy, 2022-2035
- 26.4.1.2. Clinical Scale Manufacturing Market For T Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.4.1.3. Clinical Scale Manufacturing Market For T Cell Therapies: Distribution By Geography, 2022-2035
- 26.4.2. Clinical Scale Manufacturing Market For Nk Cell Therapies, 2022-2035
- 26.4.2.1. Clinical Scale Manufacturing Market For Nk Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.4.2.2. Clinical Scale Manufacturing Market For Nk Cell Therapies: Distribution By Geography, 2022-2035
- 26.4.3. Clinical Scale Manufacturing Market For Dendritic Cell Therapies, 2022-2035
- 26.4.3.1. Clinical Scale Manufacturing Market For Dendritic Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.4.3.2. Clinical Scale Manufacturing Market For Dendritic Cell Therapies: Distribution By Geography, 2022-2035
- 26.4.4. Clinical Scale Manufacturing Market For Stem Cell Therapies, 2022-2035
- 26.4.4.1. Clinical Scale Manufacturing Market For Stem Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.4.4.2. Clinical Scale Manufacturing Market For Stem Cell Therapies: Distribution By Geography, 2022-2035
- 26.4.5. Commercial Scale: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 26.5. Commercial Cell Therapy Manufacturing Market, By Type Of Cell Therapy
- 26.5.1. Commercial Scale Manufacturing Market For T Cell Therapies, 2022-2035
- 26.5.1.1. Commercial Scale Manufacturing Market For T Cell Therapies: Distribution By Type Of Therapy, 2022-2035
- 26.5.1.2. Commercial Scale Manufacturing Market For T Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.5.1.3. Commercial Scale Manufacturing Market For T Cell Therapies: Distribution By Geography, 2022-2035
- 26.5.2. Commercial Scale Manufacturing Market For Dendritic Cell Therapies, 2022-2035
- 26.5.2.1. Commercial Scale Manufacturing Market For Dendritic Cell Therapies: Distribution By Geography, 2022-2035
- 26.5.3. Commercial Scale Manufacturing Market For Stem Cell Therapies, 2022-2035
- 26.5.3.1. Commercial Scale Manufacturing Market For Stem Cell Therapies: Distribution By Source Of Cells, 2022-2035
- 26.5.3.2. Commercial Scale Manufacturing Market For Stem Cell Therapies, 2022-2035: Distribution By Geography
- 26.6. Data Triangulation And Validation
- 27. Cell Therapy Manufacturing Market, By Type Of Manufacturer
- 27.1. Chapter Overview
- 27.2. Key Assumptions And Methodology
- 27.3. Cell Therapy Manufacturing Market: Distribution By Type Of Manufacturer, 2022, 2024 And 2035
- 27.3.1. In-house Manufacturers: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 27.3.2. Contract Manufacturing Organizations: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 27.4. Data Triangulation And Validation
- 28. Cell Therapy Manufacturing Market, By Geography
- 28.1. Chapter Overview
- 28.2. Key Assumptions And Methodology
- 28.3. Cell Therapy Manufacturing Market: Distribution By Geography, 2022, 2024 And 2035
- 28.3.1. North America: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 28.3.2. Europe: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 28.3.3. Asia Pacific: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 28.3.4. Rest Of The World: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)
- 28.4. Data Triangulation And Validation
- 29. Swot Analysis
- 29.1. Chapter Overview
- 29.2. Strengths
- 29.3. Weaknesses
- 29.4. Opportunities
- 29.5. Threats
- 29.6. Comparison Of Swot Factors
- 30. Survey Analysis
- 30.1. Chapter Overview
- 30.2. Analysis By Designation Of Respondents
- 30.3. Analysis By Type Of Cell Therapy
- 30.4. Analysis By Scale Of Operation
- 30.5. Analysis By Source Of Cells
- 30.6. Analysis By Type Of Cell Culture System Used
- 30.7. Analysis By Availability Of Fill / Finish Services
- 31. Concluding Remarks
- 32. Executive Insights
- 32.1. Chapter Overview
- 32.2. Marketing Manager, Cell Therapy, Mid-sized Company In Australia
- 32.3. Director, Organization In Uk
- 32.4. Marketing Director, Small Company In Belgium
- 32.5. Management Board Vice-president, Large Company In Poland
- 32.6. Senior Director Of Sales Advanced Therapies; Vice President Of Marketing, Small Company In Us
- 32.7. Business Administration Department Manager, Mid-sized Company In Japan
- 32.8. Chief Business Officer, Small Company In Netherlands
- 32.9. Director Of Finance And Facility Operations, Organization In Us
- 32.10. Senior Director, Very Large Company In Japan
- 32.11. Chief Executive Officer, Mid-sized Company In Uk
- 32.12. Former Chief Technical Officer, Cell And Gene Therapy, Large Company In Us
- 32.13. Former Chief Executive Officer, Small Company In Netherlands
- 32.14. Former General Manager, Small Company In France
- 32.15. Chief Executive Officer, Large Company In China
- 32.16. Executive Vice President Research And Development, Small Company In Israel
- 32.17. Former Business Development Manager, Mid-sized Company In Uk
- 32.18. Professor And American Red Cross Chair In Transfusion Medicine, Organization In Us
- 32.19. Former Co-founder And Chief Executive Officer, Small Company In Singapore
- 32.20. Former Manager, Business Development And Operations-cgmp Manufacturing Unit, Mid-sized Company In Canada
- 32.21. Manager Of Business Development, Small Company In Us
- 32.22. Former Department Leader, Cell Therapy Innovation And Development, Mid-sized Company In France
- 32.23. Former Chief Executive Officer, Mid-sized Company In Australia
- 32.24. Chief Executive Officer, Small Company In Netherlands
- 33. Appendix 1: Tabulated Data
- 34. Appendix 2: List Of Companies And Organizations
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook